Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705394 | 0.93 | PKM (0.45) | PKMSMN1; SMN2FOLH1CASP1TSHR | |
| SCHEMBL26424063 | 0.90 | FOLH1 (0.46) | PKMSMN1; SMN2FOLH1CASP1TSHR | |
| SCHEMBL6381693 | 0.90 | FOLH1 (0.51) | FOLH1TSHRALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL19225427 | 0.86 | SMN1; SMN2 (0.35) | PKMSMN1; SMN2FOLH1TSHRALDH1A1 | |
| SCHEMBL23710384 | 0.85 | FOLH1 (0.47) | SMN1; SMN2FOLH1TSHRALDH1A1MAPK1 | |
| SCHEMBL23710366 | 0.85 | FOLH1 (0.47) | SMN1; SMN2FOLH1TSHRALDH1A1MAPK1 | |
| SCHEMBL26427320 | 0.85 | FOLH1 (0.47) | SMN1; SMN2FOLH1TSHRALDH1A1MAPK1 | |
| SCHEMBL23705052 | 0.83 | FOLH1 (0.62) | FOLH1TSHRALDH1A1CETP | |
| SCHEMBL19220641 | 0.82 | LMNA (0.36) | PKMSMN1; SMN2FOLH1ALDH1A1MAPK1 | |
| SCHEMBL17533764 | 0.82 | SMN1; SMN2 (0.36) | PKMSMN1; SMN2FOLH1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| WO-2021155167-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | PKM 905/4885SMN1; SMN2 3516/4885FOLH1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.